Browse News
Filter News
Found 595 articles
-
Synthetic Biology Industry is Rising Rapidly Up to USD 80.17 Bn by 2033
4/22/2024
The global synthetic biology market size was worth around USD 14.09 billion in 2024 and is predicted to grow around USD 80.17 billion by 2033 with a compound annual growth rate (CAGR) of roughly 18.99% between 2024 and 2033 According to a new report by Nova One Advisor.
-
Solarvest Announces Annual General Meeting of Shareholders
4/3/2024
Vancouver, British Columbia--(Newsfile Corp. - April 3, 2024) - Solarvest BioEnergy Inc. (TSXV: SVS) ("Solarvest" or the "Company") is pleased to announce that it intends to hold its annual general meeting of shareholders (the "Meeting") on May 10, 2024 in Vancouver, British Columbia.
-
Devonian Names Kathryn J. Gregory to the Board of Directors and Grants Stock Options
2/29/2024
Devonian Health Group Inc. announced today that the board of directors of the Corporation (the “ Board ”) has appointed pharmaceutical industry veteran Ms. Kathryn J. Gregory to the Board, effective February 28, 2024.
-
Devonian Announces that its Subsidiary, Altius, Launches Authorized Generic of Dexlansoprazole (Dexilant®) in Canada
2/27/2024
Devonian Health Group Inc. is pleased to announce that its wholly-owned subsidiary, Altius Healthcare Inc. has launched the first authorized generic of dexlansoprazole (Dexilant®) in Canada to treat symptoms of gastroesophageal reflux disease (GERD).
-
Devonian Announces a $2.16 Million Secured Term Loan Following Repayment of $3.5 Million Long Term Loan
2/26/2024
Devonian Health Group Inc. announced that it has entered into a twelve month term loan in a principal of $2,160,000 from Fiera Private Debt Inc., following the repayment of its $3,500,000 long term loan, which matured January 17, 2024.
-
Devonian Bolsters Intellectual Property With Issuance of U.S. Patent Covering a Method of Treatment of Inflammatory Bowel Disease
2/20/2024
Devonian Health Group Inc. today announced that the United States Patent and Trademark Office (“ USPTO ”) has issued patent no. 11,723,938 B2 entitled, “ Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease. ”
-
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
2/14/2024
Precision BioSciences, Inc. announced that the company has received pre-IND regulatory feedback from the U.S. Food and Drug Administration and ex-U.S. agencies.
-
Solarvest Transition to NEX
1/12/2024
Further to Solarvest's (TSXV: SVS.H) (or "the Company"s) press releases dated May 3, 2023 and July 24, 2023 and to the Exchange's Notice to transfer to NEX dated September 15, 2023, the Company confirms that the Exchange has issued a bulletin to transfer the Company's securities to NEX effective at the opening on Tuesday, January 9, 2024.
-
U.S. Department of Energy Awards Team Led by Ginkgo Bioworks Funding to Develop Algal Crop Protection Solutions
12/19/2023
Ginkgo Bioworks announced that a Ginkgo-led team — including partners from the Pacific Northwest National Laboratory, Colorado School of Mines, and Global Algae Innovations — has been awarded funding through the U.S. Department of Energy's Bioenergy Technologies Office.
-
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
12/4/2023
Precision BioSciences, Inc. today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease.”
-
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
11/13/2023
Precision BioSciences, Inc. announced that the company will present late-breaking data at the American Association for the Study of Liver Diseases’ The Liver Meeting being held in Boston, MA.
-
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
10/26/2023
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress.
-
Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research
10/18/2023
Yield10 Bioscience, Inc. today announced that the Company has exercised its option to finalize an exclusive global, commercial license to advanced omega-3 production technology from U.K.
-
Rodent Optic Nerve Head Wins the 49th Annual Nikon Small World Photo Microscopy Competition
10/17/2023
Nikon Instruments Inc. unveiled the winners of the 49th annual Nikon Small World Photomicrography Competition.
-
Solarvest BioEnergy Announces Update on Notice of Requisition for General Meeting
8/28/2023
Solarvest BioEnergy Inc. (TSXV: SVS) ("Solarvest" or the "Company") announces that, further to its news release of August 3, 2023, a Notice of Requisition for General Meeting delivered by Garth Greenham and LMC Communications Inc. dated July 24, 2023
-
Bloomage Biotech Pioneers Sustainability Revolution: Unveiling Advanced Green Technology for Energy Conservation and Carbon Emission Reduction
8/24/2023
Bloomage Biotech, a visionary leader in biotechnology and biomaterials, employs an eco-friendly microbial fermentation process to produce hyaluronic acid and other bioactive substances.
-
ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months
8/16/2023
Zivo Bioscience, Inc. provided an update on the commercialization of Zivolife, its proprietary algal biomass as a food or food ingredient.
-
Solarvest Receipt of Notice of Requisition of a Meeting of Shareholders
8/3/2023
Solarvest BioEnergy Inc. (TSXV: SVS) ("Solarvest" or the "Company") announces, that a notice of requisition of a general meeting of shareholders (the "Requisition") was delivered to the registered office of the Company on July 24, 2023.
-
Yield10 Bioscience Files Request for Regulatory Status Review under USDA-APHIS’s SECURE Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil
7/26/2023
Yield10 Bioscience, Inc. today announced that the Company recently filed a request for a Regulatory Status Review (RSR) with USDA-APHIS Biotechnology Regulatory Services (BRS) under the SECURE Rule for proprietary elite Camelina varieties containing genes enabling the plant to produce the eicosapentaenoic acid (“EPA”) component of omega-3 oil.
-
ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food
7/26/2023
Zivo Bioscience, Inc. announces the commercialization of its proprietary algal biomass as a food or food ingredient.